sacituzumab tirumotecan (MK-2870) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  sacituzumab tirumotecan (MK-2870) / Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov) -  Dec 14, 2023   
    P2,  N=110, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
  • ||||||||||  sacituzumab tirumotecan (MK-2870) / Merck (MSD)
    Enrollment open, Enrollment change, Monotherapy, Metastases:  SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Oct 24, 2023   
    P2,  N=366, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=237 --> 366
  • ||||||||||  sacituzumab tirumotecan (MK-2870) / Merck (MSD), tagitanlimab (HBM9167) / Harbour BioMed
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (clinicaltrials.gov) -  Oct 23, 2023   
    P2,  N=175, Recruiting, 
    Not yet recruiting --> Recruiting | N=237 --> 366 Not yet recruiting --> Recruiting | N=95 --> 175 | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
  • ||||||||||  sacituzumab tirumotecan (MK-2870) / Merck (MSD)
    Enrollment open, Combination therapy, Monotherapy, Metastases:  A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (clinicaltrials.gov) -  Aug 8, 2023   
    P3,  N=356, Recruiting, 
    Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  sacituzumab tirumotecan (MK-2870) / Merck (MSD)
    New P3 trial, Combination therapy, Monotherapy, Metastases:  A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (clinicaltrials.gov) -  May 23, 2023   
    P3,  N=356, Not yet recruiting, 
  • ||||||||||  sacituzumab tirumotecan (MK-2870) / Merck (MSD)
    Enrollment open, Combination therapy, Monotherapy, Metastases:  A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  May 16, 2023   
    P2,  N=296, Recruiting, 
    Two phase 3 studies are currently planned in HR+/HER2- mBC, one in China for pts after at least one chemo for mBC and a second global for pts previously untreated with chemo for mBC, both comparing SKB264 vs investigator selected chemo. Not yet recruiting --> Recruiting